# Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy

> **NCT01916720** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 103 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** SB-480848 40 mg
- **DRUG:** SB-480848 80 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01916720
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-07
- **Final completion:** 2003-07
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01916720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01916720, "Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01916720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*